



Appendix 12 - Burkitt's lymphoma

Approved settings/ treatment line	Chemotherapy protocols	Drugs in abbreviation	Evidence Category
1st line, < 60 years, Low-risk	CODOX-M/IVAC + Rituximab	Cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin, cytarabine, rituximab, Ifosfamide, etoposide, MESNA	Category 2A, Preferred
	Dose-adjusted EPOCH-R	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A, Preferred
	R-Hyper CVAD	cyclophosphamide, vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA	Category 2A, Preferred
1st line, < 60 years, High-risk	CODOX-M/IVAC + Rituximab	Cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin, cytarabine, rituximab, Ifosfamide, etoposide, MESNA	Category 2A, Preferred
	Dose-adjusted EPOCH-R	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A, Preferred
	R-Hyper CVAD	cyclophosphamide, vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA	Category 2A, Preferred
1st line, ≥ 60 years, Low & high risk	Dose-Adjusted R- EPOCH	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A, Preferred
2nd line	Dose-Adjusted R- EPOCH	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A
	R-ICE	Ifosfamide, etoposide, carboplatin	Category 2A
	R-IVAC	rituximab, ifosfamide, etoposide, MESNA, Cytarabine, IT Methotrexate	Category 2A
	R-GDP	Gemcitabine, dexamethasone, cisplatin	Category 2A
	R-HiDAC	Cytarabine	Category 2A